{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000003","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.731609+00:00","generated_at":"2026-05-16T10:53:16.958587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO","bullets":["Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).","Cash and investments $448.3M after repaying $561M convertible notes due Nov 2025.","Active TTFields patients reached 4,620 globally; Optune Gio prescriptions +6% in Q4.","Frank Leonard, previously President, appointed CEO in December 2025.","Filed PMA for TTFields in brain metastases from NSCLC; topline data expected Q1-Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000003","json":"https://secwatch.observer/filing/0001645113-26-000003.json","markdown":"https://secwatch.observer/filing/0001645113-26-000003.md","text":"https://secwatch.observer/filing/0001645113-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000003/0001645113-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000003/nvcr-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:53:16.958587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}